Glucosaminic Acid

Glucosaminic Acid

SCHEMBL396940

N[C@@H](C(=O)O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 1.00
SLCO1B1 Q9Y6L6 1/20 1.00
PDE4A P27815 1/20 0.60
LMNA P02545 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
TDP1 Q9NUW8 1/20 0.50
OR51E2 Q9H255 1/20 0.40
SLC7A5 Q01650 1/20 0.39
KDM4E B2RXH2 2/20 0.38
SLC1A1 P43005 3/20 0.37
SLC1A3 P43003 2/20 0.33
SLC1A2 P43004 2/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
PTGS1 P23219 1/20 0.32
SLC7A11 Q9UPY5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glucosaminic Acid SCHEMBL5290846 1.00 USP2 (1.00) USP2SLCO1B1PDE4ALMNAL3MBTL1
Glucosaminic Acid SCHEMBL7642316 1.00 USP2 (1.00) USP2SLCO1B1PDE4ALMNAL3MBTL1
Glucosaminic Acid SCHEMBL30955946 1.00 USP2 (1.00) USP2SLCO1B1PDE4ALMNAL3MBTL1
Glucosaminic Acid SCHEMBL13984380 1.00 USP2 (1.00) USP2SLCO1B1PDE4ALMNAL3MBTL1
Glucosaminic Acid SCHEMBL17830012 1.00 USP2 (1.00) USP2SLCO1B1PDE4ALMNAL3MBTL1
Glucosaminic Acid SCHEMBL13010965 1.00 USP2 (1.00) USP2SLCO1B1PDE4ALMNAL3MBTL1
Glucosaminic Acid SCHEMBL27248833 0.96 USP2 (0.91) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL812543 0.93 USP2 (0.86) USP2SLCO1B1PDE4ALMNAL3MBTL1
SCHEMBL7148984 0.93 USP2 (0.86) USP2SLCO1B1PDE4ALMNAL3MBTL1
Galactitol SCHEMBL9487119 0.85 USP2 (0.73) USP2SLCO1B1PDE4ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
EP-4594520-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2025-08-06 EP claimed
EP-3958831-B1 PREBIOTIC SKIN CARE COMPOSITIONS CONTAINING CARBOXYLIC ACIDS UNIV GENT (BE) 2025-02-26 EP claimed
US-12226503-B2 Prebiotic skin care compositions containing carboxylic acids UNIVERSITEIT GENT (BE) 2025-02-18 US claimed
WO-2025019764-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS MATTERWORKS INC (US) 2025-01-23 WO claimed
EP-4437319-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION Matterworks Inc (US) 2024-10-02 EP claimed
WO-2024069235-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2024-04-04 WO claimed
US-20230322837-A1 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2023-10-12 US claimed
EP-4253394-A1 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) 2023-10-04 EP claimed
US-20230137741-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION MATTERWORKS INC 2023-05-04 US claimed
CN-1183786-A Bicyclic tachykinins antagonists, preparation thereof and their use in autagonistes composition MENARINI FARMA IND (IT) 1998-06-03 CN claimed
EP-0815126-A1 BICYCLIC TACHYKININS ANTAGONISTS, PREPARATION THEREOF AND THEIR USE IN PHARMACEUTICAL COMPOSITION A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 1998-01-07 EP claimed
WO-1996040861-A1 MICROBIOLOGICAL MEDIA FOR ISOLATION AND IDENTIFICATION OF ENTERIC PATHOGENS SUCH AS E. COLI AND SALMONELLA BIOLOG, INC. (US) 1996-12-19 WO claimed
WO-1996028467-A1 BICYCLIC TACHYKININS ANTAGONISTS, PREPARATION THEREOF AND THEIR USE IN PHARMACEUTICAL COMPOSITION A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) 1996-09-19 WO claimed
US-5191016-A Functionalized poly(hydroxyalkanoates) and method of manufacturing same YALPANI MANSSUR (US) 1993-03-02 US claimed
EP-0292087-B1 IMPROVED REDUCING AGENT AND METHOD FOR THE ELECTROLESS DEPOSITION OF SILVER LONDON LABORATORIES LIMITED (US) 1992-05-20 EP claimed
CN-1016365-B IMPROVED REDUCING AGENT AND METHOD FOR ELECTROLESS DEPOSITION OF SILVER LONDON LABORATORIES (US) 1992-04-22 CN claimed
CN-88100308-A The improvement reductive agent and the method for electroless deposition of silver 1988-12-07 CN claimed
EP-0292087-A2 Improved reducing agent and method for the electroless deposition of silver LONDON LABORATORIES LIMITED (US) 1988-11-23 EP claimed
US-4737188-A USING AN HYDROXYAMINE REDUCING AGENT LONDON LABORATORIES LIMITED (US) 1988-04-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12226503-B2 Prebiotic skin care compositions containing carboxylic acids CUTA, TYR, DSC1 USP2 1077/4885SLCO1B1 1848/4885PDE4A 1001/4885
US-20230322837-A1 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF PROC, TMPRSS2, ACE2 USP2 2873/4885SLCO1B1 4813/4885PDE4A 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.